Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns

Simply Wall St.01-08

If you have been wondering whether Abbott Laboratories at around US$127.78 is offering fair value or a premium price, this breakdown is designed to give you a clear and structured view. The stock has ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601241384?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","is_english":true,"pubTime":"2026-01-08 02:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601241384","market":"nz","top_or_hot":-1,"title":"Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns","media":"Simply Wall St.","content":"<div>\n<p>If you have been wondering whether Abbott Laboratories at around US$127.78 is offering fair value or a premium price, this breakdown is designed to give you a clear and structured view. The stock has ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-look-attractive-after-rec\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-08 02:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-look-attractive-after-rec><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you have been wondering whether Abbott Laboratories at around US$127.78 is offering fair value or a premium price, this breakdown is designed to give you a clear and structured view. The stock has ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-look-attractive-after-rec\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494617.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-look-attractive-after-rec","article_id":"2601241384","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-look-attractive-after-rec","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601241384","pubTimestamp":1767810016,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you have been wondering whether Abbott Laboratories at around US$127.78 is offering fair value or a premium price, this breakdown is designed to give you a clear and structured view.\nThe stock has recorded returns of 1.6% over the last 7 days, 2.2% over the last 30 days, 2.9% year to date, 14.8% over 1 year, 19.0% over 3 years, and 28.5% over 5 years, which many investors will weigh against current pricing.\nRecent attention on Abbott has centered on how its broad healthcare portfolio and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0122379950.USD":"贝莱德世界健康科学A2","ABT.AU":"Abundant Produce","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4082":"医疗保健设备","BK4592":"伊斯兰概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4504":"桥水持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","ABT":"雅培","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4568":"美国抗疫概念","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4581":"高盛持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4585":"ETF&股票定投概念","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","BK4566":"资本集团","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC"},"translate_title":"在最近稳定的多年回报之后，雅培实验室(ABT)的定价看起来是否有吸引力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"ABT":1.5,"ABT.AU":1.5},"content_text":"If you have been wondering whether Abbott Laboratories at around US$127.78 is offering fair value or a premium price, this breakdown is designed to give you a clear and structured view. The stock has recorded returns of 1.6% over the last 7 days, 2.2% over the last 30 days, 2.9% year to date, 14.8% over 1 year, 19.0% over 3 years, and 28.5% over 5 years, which many investors will weigh against current pricing. Recent attention on Abbott has centered on how its broad healthcare portfolio and long standing market presence fit into portfolios that seek consistency and resilience. This context is useful when you think about whether the share price and those return figures line up with what you expect from a large, diversified healthcare group. On our simple 6 point valuation checklist Abbott Laboratories scores 3 out of 6, and next we will look at what traditional valuation methods say about that score, before finishing with a framework that can help you make even more sense of where value really sits.  Abbott Laboratories delivered 14.8% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry. AdvertisementApproach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and then discounting those back to a single present value figure. For Abbott Laboratories, the model used here is a 2 Stage Free Cash Flow to Equity approach, based on cash flows reported in $. The latest twelve month free cash flow is about $6.84b, and analysts plus extrapolated estimates feed into a set of projections that extend out to 2035. For example, projected free cash flow for 2029 is $8.42b, with values beyond the analyst horizon extrapolated by Simply Wall St. Rolling all of those projected cash flows into the DCF framework results in an estimated intrinsic value of around $73.43 per share. Against a current share price of about $127.78, this implies the stock is roughly 74.0% above the DCF estimate, which in this specific cash flow model indicates it is overvalued. Result: OVERVALUED Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories may be overvalued by 74.0%. Discover 875 undervalued stocks or create your own screener to find better value opportunities. ABT Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Abbott Laboratories. Approach 2: Abbott Laboratories Price vs Earnings For a profitable company like Abbott Laboratories, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of current earnings. The higher the growth expectations and the lower the perceived risk, the higher that ratio can reasonably be, while slower growth or higher risk usually call for a lower, more conservative P/E. Abbott’s current P/E is about 16x. That sits below the Medical Equipment industry average of around 30.65x and also below the peer group average of roughly 50.76x. On the surface, that suggests the market is assigning a lower earnings multiple to Abbott compared with many companies in its sector. Simply Wall St’s Fair Ratio for Abbott is 27.92x. This is a proprietary estimate of what a “normal” P/E could look like for the company, based on factors such as its earnings growth profile, industry, profit margins, market cap and specific risks. Because it is tailored to Abbott’s characteristics rather than broad group averages, the Fair Ratio aims to be more informative than a simple comparison with peers or the sector. Comparing the Fair Ratio of 27.92x with the current P/E of 16x suggests Abbott’s shares are trading below that fair multiple, which may indicate the stock is undervalued on this metric. Result: UNDERVALUED NYSE:ABT P/E Ratio as at Jan 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1449 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, where you set out your story for Abbott Laboratories, link that story to your own revenue, earnings and margin assumptions, see the fair value that falls out of those numbers, and then compare it with today’s price so you can judge whether to buy or sell. That fair value updates automatically when fresh news or earnings arrive. One investor might build a Narrative around a higher fair value of about US$159 if they see stronger long term earnings and a higher future P/E, while another might anchor closer to US$122 if they focus on risks like pricing pressure, regulation and litigation. You can see both side by side instead of relying only on the current P/E or a single price target. Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying! NYSE:ABT 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601241384","isCrawlerRequest":true}